Takeda Opens Takeda Pharmaceuticals Mexico

Takeda Pharmaceuticals North America has established Takeda Pharmaceuticals Mexico, which will be headquartered in Mexico City. The company said that the expansion strengthens the company’s North American presence, bolstering existing operations in the US and Canada.

Reportedly, Takeda Mexico plans to file a new drug application with the Federal Commission for the Protection against Sanitary Risk (COFEPRIS) in 2010. Takeda focuses on a variety of therapeutic areas, including lifestyle-related diseases, oncology and urological diseases, central nervous system diseases, and gastroenterological diseases.

Shinji Honda, president and CEO of Takeda Pharmaceuticals North America, said: “With a population of 109 million people, Mexico represents an important expansion opportunity for Takeda. The needs of patients in Mexico fit well with our product portfolio, so we are excited to bring important medicines to this vital region.”

Bruno Ferrari, CEO of ProMexico, a federal government entity, said: “For us, it is a pleasure that Takeda has chosen Mexico to start operations. Takeda’s experience is of great importance not only because of the company’s contributions to Mexico’s health system, but also the jobs that will be brought to Mexico’s qualified labor force.”